2012 8,153,246 7,445,970 106,148 (3,541,203) (1,422,547) 1,525,239 239,173 12,506,026
Loss for the
financial
year - - - - - - (3,844,034) (3,844,034)
Exchange
differences
on
translation
of foreign
operations - - - - (311,193) - - (311,193)
Share based
payments - - - - - 67,072 - 67,072
At 31
December
2012 8,153,246 7,445,970 106,148 (3,541,203) (1,733,740) 1,592,311 (3,604,861) 8,417,871
Loss for the
financial
period - - - - - - (1,769,951) (1,769,951)
Exchange
differences
on
translation
of foreign
operations - - - - 337,464 - - 337,464
Share based
payments - - - - - 122,322 - 122,322
At 30 June
2013 8,153,246 7,445,970 106,148 (3,541,203) (1,396,276) 1,714,633 (5,374,812) 7,107,706
Attributable
to:-
Equity
holders
of the
parent
company 8,153,246 7,445,970 106,148 (3,541,203) (1,396,276) 1,714,633 (5,374,812) 7,107,706
ImmuPharma plc
CONSOLIDATED STATEMENT OF CASHFLOWS
FOR THE PERIOD ENDED 30 JUNE 2013
Notes Unaudited Audited Unaudited
6 months Year 6 months
ended ended ended
30 June 31 December 30 June
2013 2012 2012
GBP GBP GBP
Cash flows from
operating activities
Cash used in operations 3 (1,812,601) (3,448,910) (1,744,981)
Tax 302,373 196,197 -
Interest paid (56) (4,425) (652)
Net cash used in
operating activities (1,510,284) (3,257,138) (1,745,633)
Investing activities
Purchase of property,
plant and equipment (1,337) (12,632) (11,405)
Finance income 11,491 87,552 1,726
Net cash generated
from/(used in) investing
activities 10,154 74,920 (9,679)
Financing activities
(Decrease)/increase
in bank overdraft (25,861) 21,741 (3,195)
New loans - 475,020 -
Loan repayments (90,208) (139,892) (48,533)
Net cash (used in)/generated
from financing activities (116,069) 356,869 (51,728)
Net decrease in cash
and cash equivalents (1,616,199) (2,825,349) (1,807,040)
Cash and cash equivalents
at start of period 8,893,267 12,164,784 12,164,784
Effects of exchange
rates on cash and
cash equivalents 391,961 (446,168) (226,303)
Cash and cash equivalents
at end of period 7,669,029 8,893,267 10,131,441
ImmuPharma plc
NOTES TO THE INTERIM ACCOUNTS FOR THE PERIOD ENDED 30 JUNE
2013
1 ACCOUNTING POLICIES
Basis of preparation
The interim financial information in this report has been
prepared using accounting policies consistent with IFRS as adopted
by the European Union. IFRS is subject to amendment and
interpretation by the International Accounting Standards Board
(IASB) and the IFRS Interpretations Committee and there is an
ongoing process of review and endorsement by the European
Commission. The financial information has been prepared on the
basis of IFRS that the Directors expect to be adopted by the
European Union and applicable as at 31 December 2013.
The accounting policies applied are consistent with those that
were applied to the financial statements for the year ending 31
December 2012.
Income tax
Taxes on income in the interim periods are accrued using the tax
rate that would be applicable to expected total annual
earnings.
Non-Statutory accounts
The financial information set out in this interim report does
not constitute the Group's statutory accounts. The statutory
accounts for the year ended 31 December 2012 have been delivered to
the Registrar of Companies. The auditors reported on those
accounts; their report was unqualified, did not contain a statement
under either Section 498 (2) or Section 498 (3) of the Companies
Act 2006 and did not include references to any matters to which the
auditor drew attention by way of emphasis. The financial
information for the 6 months ended 30 June 2013 and 30 June 2012 is
unaudited.
Copies of this statement will be available on the Company's
website - www.immupharma.com.
ImmuPharma plc
NOTES TO THE INTERIM ACCOUNTS FOR THE PERIOD ENDED 30 JUNE
2013
(continued)
2 LOSS PER SHARE
Unaudited Audited Unaudited
6 months Year 6 months
ended ended ended
30 June 31 December 30 June
2013 2012 2012
GBP GBP GBP
Loss
Loss for the purposes
of basic and diluted
loss per share being
net loss attributable
to equity shareholders (1,769,951) (3,844,034) (1,768,884)
Number of shares
Weighted average number
of ordinary shares for
the purposes of basic
loss per share 81,532,463 81,532,463 81,532,463
Basic loss per share (2.17)p (4.71)p (2.17)p
Diluted loss per share (2.17)p (4.71)p (2.17)p
Share options and warrants have not been included in the
calculation of diluted loss per share as they are
anti-dilutive.
ImmuPharma plc
NOTES TO THE INTERIM ACCOUNTS FOR THE PERIOD ENDED 30 JUNE
2013
(continued)
3 CASH USED IN OPERATIONS
Unaudited Audited Unaudited
30 June 31 December 30 June
2013 2012 2012
GBP GBP GBP
Operating loss (1,852,929) (4,175,053) (1,968,657)
Depreciation & amortisation 27,319 50,923 27,142
Share-based payments 4,422 67,072 33,536
Decrease in trade &
other receivables 452,874 785,805 642,556
Decrease in trade &
other payables (537,824) (16,963) (586,015)
Decrease in provisions (30,371) (84,367) (92,650)
Gain/(loss) on
foreign exchange 123,908 (76,327) 199,107
Cash used in
operations (1,812,601) (3,448,910) (1,744,981)
4 SUBSEQUENT EVENTS
There have been no subsequent events since
30 June 2013 which would have a material effect
on these Interim Results.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR NKADKOBKDQCB
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024
